皓元医药: 上海皓元医药股份有限公司关于2023年限制性股票激励计划第二类限制性股票第二个归属期符合归属条件的公告

Core Viewpoint - The announcement details the fulfillment of conditions for the second vesting period of the 2023 restricted stock incentive plan, allowing 98 eligible participants to vest a total of 530,950 shares [1][15][19] Summary by Sections Incentive Plan Overview - The company approved the 2023 restricted stock incentive plan, which includes two categories of restricted stocks, with a total of 1,100,000 shares granted, representing approximately 0.73% of the total share capital at the time of the plan's announcement [2][12] - The vesting price for both categories of restricted stocks is set at 32.00 yuan per share [2] Vesting Conditions - The second vesting period for the second category of restricted stocks has been achieved, allowing for the vesting of 530,950 shares [1][15] - The vesting conditions include a 12-month employment requirement and specific performance targets based on revenue growth [3][4] Performance Targets - The performance targets for the first and second vesting periods are set at a minimum revenue growth of 25% for 2023 and 60% for 2024, respectively, based on 2022 revenue figures [4][14] - The company has reported a revenue growth rate of 67.16% for the second vesting period, meeting the performance criteria [14] Shareholder and Board Approval - The plan received necessary approvals from the board and shareholders, ensuring compliance with relevant laws and regulations [17][19] - The board's compensation and assessment committee confirmed that the vesting conditions for the second category of restricted stocks have been met [15][19] Stock Vesting Details - The vesting date for the shares will be determined based on the completion of registration procedures with the relevant authorities [18] - A total of 3,192 shares will be canceled due to the disqualification of 6 participants who left the company [15][19] Legal and Financial Advisory - Legal opinions confirm that the incentive plan's implementation complies with applicable laws and does not harm the interests of the company or its shareholders [19] - The independent financial advisor has also verified that the conditions for the vesting of the second category of restricted stocks have been met [19]